NAD+ Pharmaceuticals
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
98
NCT03406364
Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 6, 2018
Completion: Jul 24, 2020
NCT03650075
To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers
Start: Feb 25, 2019
Completion: Feb 27, 2020